Adoptive CD8+ T-cell therapy - Merck Sharp and Dohme/MD Anderson Cancer Center

Drug Profile

Adoptive CD8+ T-cell therapy - Merck Sharp and Dohme/MD Anderson Cancer Center

Alternative Names: Adoptive T-cell infusion; CD8+ T-cell therapy

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Mar 2017 University of Texas M.D. Anderson Cancer Center plans a phase I trial for Uveal melanoma (Metastatic disease) in USA (NCT03068624)
  • 28 Oct 2016 Preclinical trials in Solid tumours in USA (Infusion) before October 2016
  • 08 Sep 2016 Merck Sharp and Dohme plans a phase I trial for Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02757391)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top